Form 4: Geron Corp Director V. Bryan Lawlis Executes Option Exercise and Sale Under 10b5-1 Plan

Director V. Bryan Lawlis exercised and sold Geron Corp stock options under a pre-arranged 10b5-1 trading plan.

Summary

• On May 15, 2024, V. Bryan Lawlis, a director of Geron Corporation, executed transactions involving the company's common stock.
• Lawlis exercised stock options to acquire 35,000 shares at a price of $1.94 per share.
• Simultaneously, Lawlis sold 35,000 shares of common stock at a weighted average price of $3.75, with individual sales ranging from $3.715 to $3.790.
• These transactions were conducted under a pre-approved 10b5-1 trading plan adopted on February 14, 2024.
• Following these transactions, Lawlis no longer directly owns any common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing plan. There is no indication of positive or negative implications for the company's performance.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating compliance with insider trading regulations.

Negatives

• The director no longer directly owns any common stock after the transaction.

Risks

• While the 10b5-1 plan provides a defense against insider trading allegations, the market may react to the director's sale of shares.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Directors and officers often use 10b5-1 trading plans to manage their stock holdings in compliance with insider trading laws. These plans allow insiders to sell shares at predetermined times and prices, avoiding accusations of trading on non-public information.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among corporate insiders to manage their stock holdings and avoid potential insider trading accusations.
• Similar transactions are frequently observed in filings by directors and officers of publicly traded companies in the biotechnology and pharmaceutical sectors, such as Amgen, Gilead Sciences, and Biogen.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, depending on their interpretation of the director's stock sale.

Key Dates